Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onconova Therapeutics

0.9953
0.0000
Volume:- -
Turnover:1.32M
Market Cap:20.94M
PE:-1.10
High:0.9953
Open:0.9953
Low:0.9953
Close:0.9953
Loading ...

Traws Pharma Full Year 2023 Earnings: Beats Expectations

Simply Wall St.
·
05 Apr 2024

Onconova Therapeutics’ Strategic Acquisition and Corporate Transformation

TIPRANKS
·
04 Apr 2024

Onconova Therapeutics Buys Trawsfynydd Therapeutics

Dow Jones
·
02 Apr 2024

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

GlobeNewswire
·
02 Apr 2024

Onconova Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Reuters
·
02 Apr 2024

Onconova Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
23 Mar 2024

Onconova Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
16 Mar 2024

Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)

TIPRANKS
·
11 Mar 2024

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

GlobeNewswire
·
08 Mar 2024

Onconova Therapeutics Buy Rating: Promising Potential of Narazaciclib as a Multi-Kinase Targeting Oncology Therapy

TIPRANKS
·
13 Dec 2023

Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

GlobeNewswire
·
12 Dec 2023

BRIEF-Onconova Therapeutics Preclinical Narazaciclib Data At Sabcs Highlights Differentiated Anti-Tumor Activity

Reuters
·
09 Dec 2023

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

StreetInsider
·
09 Dec 2023

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

GlobeNewswire
·
28 Nov 2023

Onconova Therapeutics Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
17 Nov 2023

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcript

Insider Monkey
·
16 Nov 2023

Positive Financial Performance and Potential of Lead Assets Boost Onconova Therapeutics’ Buy Rating: An Analysis by Joseph Pantginis

TIPRANKS
·
15 Nov 2023

Onconova Therapeutics Q3 EPS $(0.23) Beats $(0.29) Estimate, Sales $57.00K Miss $70.00K Estimate

Benzinga
·
15 Nov 2023